![]() |
Name |
11Alpha-Methoxycurvularin
|
Molecular Formula | C17H22O6 | |
IUPAC Name* |
(5S,9S)-13,15-dihydroxy-9-methoxy-5-methyl-4-oxabicyclo[10.4.0]hexadeca-1(12),13,15-triene-3,11-dione
|
|
SMILES |
C[C@H]1CCC[C@@H](CC(=O)C2=C(CC(=O)O1)C=C(C=C2O)O)OC
|
|
InChI |
InChI=1S/C17H22O6/c1-10-4-3-5-13(22-2)9-15(20)17-11(7-16(21)23-10)6-12(18)8-14(17)19/h6,8,10,13,18-19H,3-5,7,9H2,1-2H3/t10-,13-/m0/s1
|
|
InChIKey |
LBVPDFGFLMFDPI-GWCFXTLKSA-N
|
|
Synonyms |
11Alpha-Methoxycurvularin; 11-alpha-methoxycurvularin; CHEMBL1643634; ZINC13412695
|
|
CAS | NA | |
PubChem CID | 14829838 | |
ChEMBL ID | CHEMBL1643634 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 322.4 | ALogp: | 2.5 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 93.1 | Aromatic Rings: | 2 |
Heavy Atoms: | 23 | QED Weighted: | 0.772 |
Caco-2 Permeability: | -4.667 | MDCK Permeability: | 0.00003840 |
Pgp-inhibitor: | 0.019 | Pgp-substrate: | 0.031 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.818 |
Blood-Brain-Barrier Penetration (BBB): | 0.258 | Plasma Protein Binding (PPB): | 55.74% |
Volume Distribution (VD): | 0.568 | Fu: | 37.87% |
CYP1A2-inhibitor: | 0.269 | CYP1A2-substrate: | 0.114 |
CYP2C19-inhibitor: | 0.075 | CYP2C19-substrate: | 0.107 |
CYP2C9-inhibitor: | 0.165 | CYP2C9-substrate: | 0.77 |
CYP2D6-inhibitor: | 0.389 | CYP2D6-substrate: | 0.224 |
CYP3A4-inhibitor: | 0.565 | CYP3A4-substrate: | 0.229 |
Clearance (CL): | 14.589 | Half-life (T1/2): | 0.855 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.213 |
Drug-inuced Liver Injury (DILI): | 0.899 | AMES Toxicity: | 0.164 |
Rat Oral Acute Toxicity: | 0.149 | Maximum Recommended Daily Dose: | 0.891 |
Skin Sensitization: | 0.787 | Carcinogencity: | 0.685 |
Eye Corrosion: | 0.044 | Eye Irritation: | 0.094 |
Respiratory Toxicity: | 0.769 |